NPT uses a proprietary platform technology to produce next-generation rapid diagnostics for infectious diseases. This same technology can also determine key properties of microbial pathogens such as the antibiotic susceptibility profiles of bacteria. The rising rate of antibiotic resistance makes administration of antibiotics prior to determining antibiotic susceptibility increasingly problematic. Our first product, the NucAP Pyoderma Tri-plate, rapidly determines antibiotic susceptibilities of bacterial pathogens that cause canine skin infections, providing veterinarians with same-day actionable data. Simple quenched fluorescent oligonucleotides that are engineered to yield a fluorescent signal in the presence of target pathogens are at the heart of NPT’s technology. The platform interfaces a category of biomarkers known as nucleases that serve as signal-generating molecules.

Nuclease Probe Technologies, Inc.

Nuclease Probe Technologies, Inc.'s headquarters in Boston, MA, United States

Description

People

Jobs